Home›Research›Compare›FSH vs PT-141
Peptide ComparisonFSH vs PT-141
Both are Reproductive & Hormonal peptides.
FSH
Follicle-Stimulating Hormone
No providers listed yet
PT-141
Bremelanotide
Half-life: 2–3 hours
292 providers listed
FSH carries stronger published evidence (Meta-analysis, 9 key studies) than PT-141 (RCT, 5); both are research compounds.
FSH
Half-life
—
PT-141
Half-life
2–3 hours
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | FSH |
| More provider options (0 vs 292) | PT-141 |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
FSH
PT-141
FSH
The improvement of umbilical cord mesenchymal stem cells on the ovarian microenvironment: a systematic review…
Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles
Efficacy and safety of hMG versus recombinant FSH: a meta-analysis
Revisiting ESR in PCOS: an easily obtainable link to immune and metabolic dysregulation.
+5 more
PT-141
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications…
The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal wom…
Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder
+1 more
About FSH
Binds FSH receptors on Sertoli cells in testes to support sperm maturation and inhibin B production. In women, binds granulosa cell FSH receptors to drive follicular growth and estradiol production.
About PT-141
PT-141 is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly within the hypothalamus. Unlike peripherally acting agents, it modulates sexual arousal at the CNS level via dopaminergic pathways, independent of vascular mechanisms. Bremelanotide received FDA approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
FSH
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
PT-141
Source: FDA label
FDA prescribing information for bremelanotide identifies transient blood pressure elevation as the primary safety concern. Baseline cardiovascular assessment and BP monitoring are recommended.
PT-141
Oxytocin
Research suggests PT-141 and Oxytocin may produce complementary sexual health effects when combined. PT-141 activates central melanocortin receptors involved in arousal signaling, while oxytocin modulates bonding, reward, and peripheral reproductive pathways.
Antihypertensive medications
Research notes that PT-141 may influence cardiovascular hemodynamics via central melanocortin pathways. Combined use with antihypertensive medications may require monitoring. Consult your prescriber before combining.
FSH
Not enough vendor pricing yet.
PT-141
Where to source these peptides
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Reproductive & Hormonal Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). FSH vs PT-141 — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/fsh/pt-141